Endo Narcan
Executive Summary
Shortages of naloxone are due to shutdown of DuPont sterile manufacturing facility, Endo explains (1"The Pink Sheet" March 19, p. 16). DuPont says manufacturing facility was closed for routine repair and maintenance. Endo expects production to be resumed by the end of March. DuPont's Manati, Puerto Rico facility received a warning letter in June 2000 for deviations from good manufacturing practices
You may also be interested in...
Naloxone shortage
FDA contracts Canadian company Sabex to supply morphine antagonist pending shortage resolution. Narcan manufacturer Endo had experienced manufacturing difficulties due to DuPont plant shutdown (1"The Pink Sheet" March 26, In Brief). According to the American Society of Health-System Pharmacists, Endo plans to release back orders by early June, while Abbott expects releases in April and May. Sabex' naloxone will not be available for intrathecal use
Naloxone shortage
FDA contracts Canadian company Sabex to supply morphine antagonist pending shortage resolution. Narcan manufacturer Endo had experienced manufacturing difficulties due to DuPont plant shutdown (1"The Pink Sheet" March 26, In Brief). According to the American Society of Health-System Pharmacists, Endo plans to release back orders by early June, while Abbott expects releases in April and May. Sabex' naloxone will not be available for intrathecal use
Abbott Doubles Fentanyl Production To Address Hospital Shortages
Abbott has doubled the production of fentanyl to respond to supply shortages of the anesthetic in hospitals around the country, the company said.